newsfilter
← Latest News
Business Wire·

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EQ

Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on August 29, 2025, the Compensation Committee of Equillium's